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SUMMARY
The neuropeptide substance P is known to
have mnemogenic and reinforcing actions and
can exert neurotrophic and regenerative
effects in vitro as well as in vivo. Furthermore,
our previous work in the rat showed that
either pre- or post-lesion treatment with
substance P can promote functional recovery
in cases of partial nigrostriatal dopamine
lesions. Other work has provided evidence that
the effects of substance P might be
differentially encoded by its C- and N-terminal
fragments. The C-terminal fragment was
found to be reinforcing, whereas the
mnemogenic as well as neurotrophic
properties have been ascribed to the
N-terminal sequences. Given these relations,
we asked here whether pre-lesion treatment
with either a C- or an N-terminal fragment of
substance P might differentially affect the
behavioral and neurochemical outcome of
nigrostriatal dopamine lesions. Therefore,
either substance P1-7 or substance P5-11
(37 nmol/kg each) was administered intraperi-
toneally daily for eight consecutive days before
unilateral 6-hydroxy-dopamine lesions of the
substantia nigra. Control rats received pre-
lesion treatment with vehicle. Furthermore, we
investigated the effects of pre-treatment with
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Boc-cholecystokinin-4 (0.91 nmol/kg), as we
had found an increase in dopamine
metabolism in animals that were pre-treated
with cholecystokinin-8 in a former study. In
accordance with our previous work, drug
treatment effects were observed when
excluding animals with most severe dopamine
lesions: In animals with partial lesions
(residual neostriatal dopamine levels of more
than 10%), lesion-dependent asymmetries in
turning behavior were observed in animals
that were pre-treated with vehicle-, substance
P1-7, or Boc-cholecysto-kinin-4, whereas
turning after pre-treatment with substance
Ps- was not significantly asymmetrical.
Furthermore, the ipsi- and contra-lateral
neostr’iatal dopamine levels did not differ
significantly in this group. Moreover, pre-
treatment with substance Ps- affected
dopamine metabolism in the neostriatum and
in the venral striatum, as indicated by
increased ratios of dihydroxyphenyllic acid to
dopamine. The data provide the first evidence
that the promotive effects of substance-P
treatment in the unilateral dopamine lesion
model might be mediated by its C-terminal
and might depend on actions on residual
dopamine mechanisms.
INTRODUCTION
The neurotachykinin substance P (SP)
enhances reinforcement and learning and
promotes functional recovery after lesions of the
nigrostriatal dopamine (DA) system (for review
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see /17/). Furthermore, the evidence shows that
these functional effects might be differentially
encoded by its C- and N-terminals: The
mnemogenic effect of SP is attributed to its
N-terminal amino acid sequences, whereas the
reinforcing actions of SP are ascribed to the
C-terminal (for review see/17-18/). Additionally,
neurochemical studies have shown that the
reinforcing effects of SP and its C-terminal are
related to enhanced DA activity in the ventral
striatum/6-8/, whereas the N-terminal fragment
SP1-7 had no such effect /6/. Apart from these
mnemogenic and reinforcing actions, SP was
repeatedly found to exert neurotrophic as well as
neuroprotective functions (for example, /19,20,
26,8,39-41/), and in-vitro investigations showed
that this capacity might be related to the
N-terminal amino acid sequence. Thus, for
example, the N-terminal amino acid sequences of
SPI-4, and the dipeptides SP1-2 and SP3-4 were
found to enhance neuronal growth/24,25,27/.
Regarding brain lesions, most behaviorally
promotive effects of neurokinins have been found
in cases of unilateral 6-hydroxydopamine
(6-OHDA) lesions of the nigrostriatal DA system
/.2,26,28/. In this hemiparkinsonian model,
unilateral damage of nigrostriatal DA neurons
leads to ipsi-lateral asymmetries in turning and
scanning, from which the animals can recover
over time (reviewed in/10,34,35/). Our previous
work using this lesion model showed that pre-
lesion treatment with SPI-I promoted behavioral
recovery and affected residual DA activity in the
neostriatum and in the ventral striatum. In
contrast, pretreatment with chole-cystokinin-8
(CCK-8), another neuropeptide that is neuronally
associated to the nigrostriatal DA system and
known to display neuroprotective properties
/13,21,32/, did not have behaviorally promotive
effects in the 6-OHDA lesion model, and affected
residual DA activity only in the neostriatum/28/.
As treatment with CCK-8 did not affect the
behavioral deficits, we concluded that the
increased DA metabolism in the ventral striatum,
which was induced by the systemic treatment
with SPI-1, might be crucial for the reduction of
ipsiversive turning behavior. Importantly, these
effects were observed in animals with partial but
not complete damage of the striatal DA system,
which indicates that a critical amount of residual
dopamine neurons is necessary for drug
treatments to be therapeutically effective/2,26,28/
(for further discussion see/35/).
In contrast to the experimental findings with
the complete amino acid sequence of SP, no data
are available yet in the lesion model regarding the
effectiveness of its C- and N-terminal fragments.
Therefore, we investigated the effects of systemic
pre-lesion treatments with either a C- or N-
terminal fragment of SP (SP.7, SPs.), or with
the Boc-CCK-4 fragment. Rats received eight
intraperitoneal injections of either vehicle, SP-7,
SPs_ (37 nmol/kg each), or Boc-CCK-4 (0.91
nmol/kg) before unilateral 6-OHDA lesions of the
substantia nigra. Beginning with the first day after
lesion, the rats were monitored for asymmetries in
turning behavior on every second day for 2
consecutive weeks. Finally, to analyze the degree
of DA damage and possible changes in residual
DA activity, neostriatal and ventral striatal brain
samples were taken. Because previous lesion
studies had pointed at the critical role of partial
DA lesions, we focused our analysis on animals
in ’which residual neostriatal DA levels on the
lesion side were at least 10% ofthe intact side. As
indicated by the behavioral and neurotrophic
studies cited above, differential effects of the
peptide fragments might be expected: From
reports regarding neurotrophic actions, beneficial
behavioral effects might be expected with the
N-terminal of SP and with the CCK-4 fragment
/24,25,27/. In contrast, when considering actions
on DA activity, recovery-promoting effects might
be more likely with the C-terminal of SP.
METHODS
Subjects
Sixty 3-mo-old male Wistar rats (Tierver-
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220-280 g at the beginning of the experiment,
were housed in groups of 5 animals each under
standard laboratory conditions. The animals were
maintained under a 12-hour light/dark cycle
(lights on at 7"00, lights off at 19:00), and had
free access to food and water. Before the
experiment, the rats were handled daily for one
week.
under stereotactic surgery (AP-5.3 mm, ML +
2.00 mm, DV-8.0 mm) /29/. Therefore, an
injection cannula was lowered into the pars
compacta of the SN, and 1 tl of 6-OHDA was
injected by means of an infusion pump (Harvard
Apparatus) at a rate of 0.4 l/min. After the
infusion, the needle was left in place for another 3
min.
Drug treatment Behavioral testing
SP1-7 (MG 900.14; Sigma Mtinchen) and
[pGlu5,MePhe8,Sar9]-SPs_ (DIME-C7, MG
880.13; Sigma, Mtinchen) were dissolved in 0.01
M acetic acid and phosphate buffered saline (pH
7.4) to final concentrations of 37 nmol/kg. This
dose was chosen because it is equimolar to the
recovery-promoting dose of the complete
sequence of SP /26,28/ and because it has been
repeatedly shown to be effective in facilitating
learning, to have reinforcing effects (for review
see/17,18/), and to increase DA release/6/. Boe-
CCK-4 (MG 697.7; Dr. Henklein, Institute of
Pharmacology and Toxicology, Humboldt
University, Berlin) was dissolved in the same
vehicle to a concentration of 0.91 nmol/kg. This
dose had been reported to display memory-
enhancing effects (for example/14/); furthermore,
this dose is equimolar to that of CCK-8 used in
our previous lesion study/28/. All injections were
made with syringes that had been rinsed with 5
mM acetic acid. On eight consecutive days, the
rats received once daily ip injections of either
SP-7 (n=18), SP5- (n=18), Boc-CCK-4 (n=ll),
or vehicle (n=13). The animals were weighed
daily to allow for exact calculation of the
injection volume (1 ml/kg). The injections were
administered between 15:00 and 18:00.
6-OHDA lesion
6-OHDA-hydrobromide (Sigma, Mtinchen)
was dissolved to a concentration of 4 mg/ml in
ice-cold saline (containing 0.2 mg/ml ascorbic
acid). On day 9, the animals were anesthetized
with equithesin (3 ml/kg) and received unilateral
6-OHDA injections into the substantia nigra
Beginning with the first day after lesion,
turning behavior was measured in an open field
on every second day for 2 consecutive weeks with
a video-image analyzing system (described in
detail elsewhere/33/). Behavioral testing (15 min
each) was carried out between 10"00 and 15:00
under dim red light. Turning was measured as the
number of left or right quarter-turns within a
diameter of less than 30 em.
It has repeatedly been shown that behavioral
asymmetries in the present kind of 6-OHDA
lesion are most pronounced during the first 3 days
after toxin administration; thereafter, the animals,
at least those with partial neostriatal DA damage
(for review see/34/), can recover to symmetry.
Thus, if a treatment acts protectively or promotes
behavioral recovery, then such an action should
display itself as a lack or reduction of asymmetry
on days 1+3 after lesion. In our previous lesion
study with SPI-ll/28/, the promotive effect of the
peptide on behavior was observed at that initial
time period, but not thereafter. Therefore, we
used the same kind of behavioral analysis here;
that is, we pooled behavioral data into blocks
consisting of days 1+3, days 5+7, days 9+11, and
days 13+15. A focused statistical analysis was
performed on the initial post-lesion period
(days 1+3) comparing ipsi- vs. contraversive
turning within a treatment group by means of
paired t-tests (one-tailed).
Neurochemical and histological analysis
One week after the last behavioral test, the
animals were first anesthetized with equithesin
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dissected, and neostriatal and ventral striatal
tissue samples ipsi- and comralateral to the side
of the 6-OHDA lesion were analyzed for their
concentrations of DA and DOPAC by means of
high performance liquid chromatography with
electrochemical detection. The remaining caudal
parts of the brains were placed into a standard
formalin solution and underwent subsequent
histological survey regarding cannula placement.
From the tissue concentrations of DA in the
ipsilateral and contralateral neostriatum, we
computed the residual DA levels on the side of
the lesion as percentages of the contralateral side
(for example see /11,26,28/). The values were
taken as indices of lesion size. As our former
study had shown that pre-lesion treatment with
SP_ promoted behavioral recovery only in
animals whose ipsilateral residual DA levels in
the neostriatum were at least 10% of the
respective contralateral side/28/, we excluded all
animals with more severe lesions. Finally, we
computed the ipsi- and contralateral metabolite/
neurotransmitter ratios (DOPAC/DA). These
neurochemical values were compared either (1)
within a given group by means of 2-tailed paired
t-tests or (2) among all treatment groups by
means of one-way analyses of variance
(ANOVAs) and post-hoe Duncan’s tests for
multiple comparisons.
RESULTS
Exclusion of animals on the basis of histological or
neurochemical criteria
No animal had to be discarded because of
inaccurate cannula placement. The post-mortem
neurochemical analysis showed that in four
animals, who had received pre-lesion treatment
with SP1-7, neostriatal DA levels on the side of
lesion were less than 10% of the intact side; the
respective numbers of animals were seven in the
SPs_l-group, two in the CCK-4-group, and two
in the vehicle-treated group. After the exclusion
of these animals, the group sizes were: SP1-7
(n=14), SPs-11 (n=l 1), CCK-4 (n=9), and vehicle
(n=l 1).
Behavioral and neurochemical results in animals
with partial neostriatal DA lesions
Behavior. The analysis of ipsi- and contra-
lateral turning behavior on post-lesion days 1+3
yielded ipsiversive asymmetries (paired t-test;
one-tailed) in the groups that were pre-operatively
treated with SP-7 (p=.006), CCK-4 (p=.013), and
vehicle (p=.046), but a trend for an asymmetry
was seen only in the group that had received
SPs-11 (p=.068, Table 1).
Neurochemistry. In the neostriatum, ipsilateral
DA levels (Table 2) were decreased in the group
treated with SP-7- (p=.003; 2-tailed paired t-test
ipsi vs. contra), CCK-4- (p=.004), and vehicle
(p<.001). In contrast, a trend for an asymmetry
was seen in animals treated with the C-terminal
fragment (SPs-11, p=.082). No between-group
differences were found with respect to ipsi-
(ANOVA, p=.522) or contralateral DA levels
(p=.480). Furthermore, no within-group
differences between ipsi- and comralateral neo-
striatal DOPAC/DA ratios were observed (Fig. 1)
in any of the four treatment groups (paired t-tests;
p-values between. 166-.516). Differences between
groups did occur, however, because the
contralateral DOPAC/ DA ratios in the SPs-11-
treated group exceeded those of all three other
treatment groups, whereas the ipsilateral
DOPAC/DA ratios in this group were higher than
those of animals treated with SPs-11 (Duncan’s
test, p-values <.05).
In the ventral striatum (Table 2), the ipsilateral
DA levels were reduced in the group treated with
the N-terminal fragment of SP (p-.028; vs.
contra; 2-tailed paired t-test), whereas those in the
groups treated with SPs-11 (P=.119), CCK-4
(p-.595), and vehicle (p=.226) did not differ.
Comparing ipsi- or contralateral DA levels
between groups did not yield indications for
differences (ANOVAs; ipsi" p=.555; contra:
p=.250). No asymmetries occurred between ipsi-
and contralateral DOPAC/DA ratios (Fig. 2) in
any of the four groups (2-tailed paired t-tests;
SP1-7 p--.094, SP5-11 p--.995, CCK-4 p-.394, and
vehicle p=.272). These ratios differed, however,
between groups on either side (ANOVAs; ipsi"
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showed that contralateral DOPAC/DA ratios in
the SPs_l-treated group exceeded those of the
CCK-4- and vehicle-groups (Dtmcan’s test,
p<.05). Furthermore, the ipsilateral DOPAC/DA
ratios of the groups tretaed with SP-fragments
were higher than in the CCK-4-treated group
(Duncan’s test, p<.05).
Behavioral and neurochemical results irrespective
of actual lesion size
The preceding analysis showed that pre-lesion
treatments with SP-fragments differentially
affected he behavioral and neurochemical
outcome of the lesion. As expected from our
TABLE 1
Turning behavior in animals with partial lesions
Days after lesion Turning behavior SP1-7 SP5-11 BocCCK-4 Vehicle
1+3 ipsi 93.4+14.3"* 112.1+28.6 105.3+12.9" 96.1+15.6"
contra 46.1+5.6 55.3+/-7.5 55.2+7.9 54.8+8.8
5+7 ipsi 81.4+11.1 95.2+19.4 116.0+18.0 81.2+11.9
contra 77.1+9.8 79.5+/-7.8 90.0+13.0 80.1+11.1
9+ 11 ipsi 78.6 +9.9 85.0+ 14.8 90.8+ 17.2 69.8+5.8
contra 64.6+6.4 68.4+7.1 69.4+8.5 66.5+6.9
13+15 ipsi 73.6+9.7 73.4+11.8 89.3+16.4 76.8+ 11.0
contra 50.9+6.3 57.5+/-6.5 60.3+8.7 56.4+6.3
Tuming ipsi- and contraversive to the side of 6-OHDA lesion in rats in which residual neostriatal DA levels exceeded 10 % of
the intact side. Data reflect quarter turns (means +SEM) measured on post-lesion days +3, 4+7, 9+ 11, and 13+ 15. Asterisks
indicate differences between ipsi- and contraversive turns according to 1-tailed paired t-tests (* p<.05; ** p<.01).
TABLE 2
Dopamine in animals with partial lesions
SP1-7 SP5-11 BocCCK-4 Vehicle
Neostriatum
DA ipsi 3.64+0.56** 4.23+ 1.03 2.83+0.83** 4.54+/-0.84***
DA contra 7.11+/-0.97 8.91+2.55 9.09+ 1.75 10.75+1.46
Ventral Striatum
DA ipsi 4.66+/-0.72* 4.664-0.64 4.11+ 1.03 6.34+ 1.81
DA contra 7.55+0.93 10.08+3.35 5.11+ 1.42 18.35+9.01
Dopamine (DA) levels in the neostriatum and ventral striattma ipsi- or contralateral to the side 6-OHDA injection. The data,
which reflect tissue concentrations (lag/g brain tissue, wet weight; mean+SEM), are taken from rats in which residual neostriatal
DA levels exceeded 10 % of the intact side. Asterisks indicate differences between the ipsi- and contralateral side according to
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previous experiment /28/, these findings were
obtained in animals with partial neostriatal DA
lesions. To test whether the results were depend-
ent on partial lesions, we performed a similar data
analysis as above, but now we included also those
animals with more severe DA lesions.
When all animals irrespective of their residual
neostriatal DA level were analyzed (Table 3),
then all groups showed pronounced ipsiversive
asymmetries in turning behavior (1-tailed paired
t-test; SPl-7: p=.002, SPs-ll: p=.003, CCK-4:
p=.004, vehicle: p=.016). Similarly, now all four
groups showed pronounced DA depletions (Table
4) in the neostriatum (2-tailed paired t-test; SP1-7:
p<.0001, SPs_l: p=.002, CCK-4: p=.001, vehicle:
p<.00001). The neostriatal DA levels did not
differ between groups (ANOVA; ipsi" p=.581;
contra: p=.424). The neostriatal DOPAC/DA
ratios (Table 4) did not differ either within groups
(paired t-tests; SP1-7: p=.472, SPs-ll" p=.159,
CCK-4: p=.066, vehicle: p=.122) or between
groups (ANOVAs; ipsi: p=. 169; contra: p=. 184).
NEOSTRIATUM
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0,50
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contra
Fig. 1" Ratios ofDOPAC/DA (means+SEM) in the neostriatum ipsi- (full bars) and contralateral (gray bars) to the
side of 6-OHDA injection. Data were taken from animals with partial neostriatal DA depletions (i.e.
neostriatal residual DA levels >10%). Before the 6-OHDA lesion, the animals had been treated
systemically for 8 days, either with SP1-7 (14), SP5-11 (n=l 1), CCK-4 (n=9) or with vehicle (n=l 1).
Statistical analysis was performed using ANOVAs followed by Duncan’s test: * indicates a difference
(p<.05) in comparison with the SP1-7 group; # indicates differences (p<.05) in comparison with vehicle,
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In the vemral striatum (Table 4), ipsilateral
DA levels were reduced in the group pre-treated
with the N-terminal of SP (2-tailed paired t-test,
ipsi vs. contra, p=.011). For SP5-11, CCK-4, and
vehicle, the respective p-values were .069, .174,
and .210. The DA levels did not differ between
groups (ANOVAs; ipsi: p=.445; contra: p=.301).
The ipsi- and contralateral DOPAC/DA ratios
(Table 4) were balanced within all four groups
(paired t-testS; SPI-7" p=.612, SP5-11" p=.368,
CCK-4: p=.289, vehicle: p=.700). Between-group
comparisons did not indicate substantial
differences on the contra-lateral side (ANOVA;
p=.221), in contrast to ipsilateral DOPAC/DA
ratios (ANOVA; p=.050), which were higher in
the SP1-7 than in the CCK-4-treated group
(Duncan’s test, p<.05).
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VENTRAL STRIATUM
SP1-7 SP5-11 BocCCK-4 Vehicle
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Fig. 2: Ratios ofDOPAC/DA (means+SEM) in the ventral striatum ipsi- (full bars) and contralateral (gray bars) to
the side of 6-OHDA injection. Data were taken from animals with partial neostriatal DA depletions (i.e.
neostriatal residual DA levels >10%). Before the 6-OHDA lesion, the animals had been treated systemically
for 8 days, either with SP1-7 (14), SPs-I (n=l 1), CCK-4 (n=9) or with vehicle (n=l 1). Statistical analysis
was performed using ANOVAs followed by Duncan’s test" # indicates a difference (p<.05) in comparison
with vehicle, and CCK-4.84 S. NIKOLAUS, J.P. HUSTON, R.K.W. SCHWARTING
TABLE 3
Turning behavior irrespective of lesion size
Days SP1-7 SP5-11 BocCCK-4 Vehicle
1+3 ipsi 100.1+13.8 ** 130.4+21.6 ** 116.2+15.3 ** 108.5+17.2 *
contra 42.8+5.5 45.1+/-6.2 47.2 +8.4 50.5 +/-8.2
5+7 ipsi 83.9+9.9 99.4+3.2 126.3 +/-20.3 89.5+/-12.4
contra 73.1+8.3 72.3+7.7 77.6+/-3.5 76.3+10.6
9+1 ipsi 76.7+/-8.3 85.6+9.7 90.9+5.0 79.4+/-9.
contra 60.7+5.7 62.3+5.8 62.5+8.7 63.8 +/-6.8
13+15 ipsi 72.8+8.3 71.7+/-7.2 90.7+/-5. 92.1 +16.2
contra 48.6+/-5.3 49.4+/-5.4 55.1+/-8. 52.8 +6.0
Turning ipsi- and contraversive to the side of 6-OHDA lesion irrespective of neostriatal lesion size. Data reflect quarter turns
(means +SEM) measured on post-lesion days 1+3, 4+7, 9+11, and 13+15. Asterisks indicate differences between ipsi- and
contraversive turns according to 1-tailed paired t-tests (* p<.05; ** p<.01).
TABLE 4
Dopamine and DOPAC/DA ratios irrespective of lesion size
SP 1-7 SP5-11 BocCCK-4 Vehicle
Neostriatum
DA ipsi 3.11 +/-0.54"**
contra 7.11+0.54
2.82+/-.76** 2.47+/-0.72**" 3.94+/-0.82***
9.80+/-.86 9.40+.4 10.73+/-.23
DOPAC/DA
ipsi 187+0.0 9
contra 0.206+/-0.022
4.685+/-2.881 0.601 +/-0.232 0.180+/-0.022
0.439+/-0.184 0.134+/-0.016 0.147+/-0.012
Ventral Striatum
DA ipsi 4.44+0.45*
contra 9.36+/-1.85
4.17+/-0.53 3.754-0.91 5.60+1.60
8.134-2.17 6.95+ 1.73 16.05+/-7.72
DOPAC/DA
ipsi 0.180+0.02 0.176+0.07 0.128+/-0.023 0.168+/-0.02
contra 0.174+/-0.007 0.189+0.04 0.151+/-0.09 0.162+/-0.0
Dopamine (DA; g/g brain tissue, wet weight; mean+SEM) levels and DOPAC/DA ratios in the neostriatum and ventral
striatum ipsi- or contralateral to the side 6-OHDA injection. The data are taken from all rats irrespective of neostriatal lesion
size. Asterisks indicate differences between the ipsi- and contralateral side according to 2-tailed paired t-tests (* p<.05,
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DISCUSSION
This experimem provides the first evidence
that systemic pre-treatments of rats with either the
C- or the N-terminal fragments of SP can
differentially affect the outcome of unilateral,
nigrostriatal DA lesions, given that the lesions are
partial. Thus, only after excluding animals in
which neostriatal DA levels on the side of lesion
fell below 10% of the contralateral side, did we
observe that the group pre-treated with SPs-11 did
not show a significant asymmetry in turning
behavior, whereas the other three groups did so.
In parallel, neostriatal DA levels on the side of
6-OHDA injection were not significantly
decreased in the group pre-treated with SPs-11, in
contrast to the groups pre-treated with SP-7,
CCK-4, or vehicle, in which the ipsilateral DA
levels were lower than those of the contralateral
side. Finally, the group treated with SPs-11
showed several indications for changes in striatal
DA activity: The contralateral neostriatal
DOPAC/DA ratio exceeded those of the other
treatment groups, and those of the N-terminal
group on the ipsilateral side. Also, in the ventral
striatum, the animals that had received the
C-terminal fragment of SP displayed higher
contralateral DOPAC/DA ratios when compared
with the groups treated with the CCK-fragment or
vehicle. Thus, this experiment generally supports
previous findings that SP can be behaviorally
promotive in case of nigrostriatal DA damage,
and that this effect may be related to changes in
DA mechanisms /2,26,28/. Furthermore, the
present study indicates that these effects may be
linked to the C-terminal, but not to the
N-terminal, of the peptide.
The CCK-fragment
In contrast to the C-terminal fragment of SP,
pre-lesion treatment with CCK-4 had no effect on
tuming behavior, neither in the subsample of
animals with partial lesions nor when also
including those with more severe lesions. This
result extends our previous findings with CCK-8
/28/, wherein pre-lesion treatment did not
promote functional recovery. Treatment with
CCK-8 affected neostriatal DA activity (namely,
increased DOPAC/DA ratios), but had no effect
in the ventral striatum/28/, and we assumed that
this lack of effect in the ventral striatum was
related to that on behavioral recovery. CCK-4
treatment had no DA-activating effect on either
structure. Thus, one may conclude either that
CCK-4 did not reach the brain in sufficient
amounts to be neurochemically effective or that
this shorter amino acid sequence of CCK has no
(or no lasting) effect on the regulation of striatal
DA activity. Altogether, the results of this and the
preceding study /28/ provide no evidence that
systemic pre-lesion treatment with CCK, a
peptide that is closely related to DA neurons in
the brain, has beneficial effect in the case of
nigrostriatal DA damage.
The SP-fragments
Our previous studies had shown that either
pre- or post-lesion treatment with SP can be
behaviorally promotive in the partial DA lesion
model because systemic peptide treatments
promoted functional recovery or even prevented
deficits from occurring/26,28/. The results of the
preent experiment indicate that these effects may
be related to the C-terminal of the peptide
because only the group treated with SPs-I
showed promotive effects on turning behavior.
Similar to our previous study with SPI-ll/28/,
the behavioral effects of SPs-11 could be
measured only when the animals with the most
severe lesions were discarded from evaluation.
Evidently, a minimum number of intact
nigrostriatal neurons is necessary for SPs-, as
well as for SP_, to exert their effects. Similar
conclusions were also drawn in a previous study
with a neurokinin-3 agonist /2/ and in other
studies in which the promotive effects of growth
factors were investigated (for example/5,36,37/).
Altogether, these findings point to the importance
of studying partial, in contrast to total, striatal DA
depletions when investigating the effectiveness of
treatments in animal models of striatal DA
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Apart from behavior, pre-lesion treatment with
NPs-I affected striatal DA activity: After
excluding animals with more severe lesions (i.e.
residual DA levels <10%), ipsi- and contralateral
neostriatal DA levels no longer differed
significantly in this group. Furthermore, the
SPs_ll-treated animals had higher DOPAC/DA
ratios in the neo- and ventral striatum. When
discussing the possible mechanisms of these
actions, various aspects must be considered: As
NPs-11, which can penetrate the blood-brain-
barrier/1/, was administered intraperitoneally,
this fragment might have acted peripherally
and/or centrally. For example, SP plays a role in
the gastro-intestinal and immune systems, renal
function, blood flow, and pain perception (for
example, /30,31/. Thus, SPs-11 might have
indirectly affected processes in the central
nervous system via actions on these mechanisms.
Alternatively, it should be considered that intra-
peritoneal as well as central injections of SP and
SPs-I can enhance striatal DA, and that these
effects can be rather long lasting/6-8,32/. Such
DAergic effects were not shared by the N-
terminal /6/. As compensatory changes in
DAergic mechanisms are thought to play a critical
role for functional recovery after nigro-striatal
DA damage (for review see /34,35/), one can
hypothesize that the DAergic actions of SPs-11
were critical for its behavioral effect, and that the
previous behavioral and neurochemical findings
observed with SP /26,28/ were mediated by its
C-terminal fragment. Furthermore, it can be
concluded that the N-terminal, which can be
neurotrophic in-vitro /24,25,27/, appears to be
ineffective, at least in the case of treatments
preceding 6-OHDA lesions. Thus, one might
assume that in the 6-OHDA model, neurotrophic
actions of SP, which have been suggested to be
critical in neurodegenerative diseases like
Alzheimer’s or Parkinson’s disease /3,4/, come
into play once the lesion has been placed, and that
the N-terminal might therefore become effective
when given post- rather than pre-lesion.
In our previous studies, we found no evidence
for a protective action of SP because the degree of
DA damage was not affected by either pre- or
post-lesion treatment/26,28/. Therefore, one may
assume that the present lack of significant
asymmetry in neostriatal DA levels after pre-
treatment with SP5-11 reflects compensatory DA
mechanisms rather than a protective action
against damage. As the indications of increased
DA activity were observed in both hemispheres,
one can furthermore assume that DAergic
mechanisms on the intact (contralateral) side had
played a role. Interestingly, evidence has been
presented for compensatory increases in the intact
substantia nigra, which also sends crossed
efferents to the damaged neostriatum /16/.
Changes in these crossed connections from the
intact side were shown to be related to recovery
from unilateral 6-OHDA studies/16/. Thus, one
can speculate that the increased contralateral
DOPAC/DA ratios observed here in the SPs-11
treated group might reflect such a compensatory
increase in the activity of the intact substantia
nigra.
In this experiment with SPS-ll and in the
preceding experiment with SPI-ll/28/, changes in
DA activity were observed not only in the
neostriatum but also in the ventral striatum.
Interestingly, DAergic mechanisms in the ventral
striatum, especially its nucleus accumbens, have
been related not only to compensatory
mechanisms after 6-OHDA lesions (for review
see/34/) but also to mechanisms of reinforcement
/11,23/. Thus, drugs having reinforcing effects are
known to increase the release of DA in the
nucleus accumbens /9/. Such reinforcing and
neurochemical actions are shared by SP and its
C-terminal fragment, but not by the N-terminal
/6-8,17,18/. Therefore, one can speculate that DA
mechanisms that are critical for reinforcement
also play a role in mechanisms of functional
recovery after nigrostriatal DA lesions.
When discussing all these possible actions,
however, one should consider that all drug
treatments in the present experiment had been
terminated before the lesions were made, which
leads to the following considerations: First, one
might assume that treatment with SP5-11 had
direct, long-term consequences that outlasted the
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an effect was obtained in a previous study in old
rats, in which the beneficial effect on water maze
performance was still observed one week after
terminating peripheral treatment with SP /15/.
Altematively, it is possible that the present
findings in the lesion model were determined, or
at least affected, by mechanisms of drug
withdrawal. Compensatory changes in response to
prolonged drug treatments and/or their
withdrawal are especially likely in case of drugs
that act as reinforcers and that increase ventral
striatal DA release (for review see/9,23/). Thus,
one might assume, for example, that the DAergic
changes observed here after SP_, and previously
after SP_ /26/, actually reflect compensatory
responses to drug treatment and/or withdrawal
rather than compensatory responses to the lesion.
If so, it might be possible that such drug-
dependent compensatory responses provide the
prerequisites for compensation for functional
recovery. Furthermore, it might be interesting to
test whether pre-lesion treatment with (and thus
withdrawal from) other reinforcing and DA-
releasing drugs (like opiates, or stimulants) affect
recovery in this partial DA lesion model.
Altogether, the present study provides
evidence that systemic pre-lesion treatment with
SP5-1, but not with SPI-7 or CCK-4, can have
promotive behavioral effects in the case of partial
unilateral DA lesions. The effects were paralleled
by changes in neostriatal and ventral striatal DA
activity, which may reflect promotive influences
on compensatory DAergic responses after lesion,
and/or interactions with compensations after
withdrawal from prolonged peptide treatment.
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